Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exagen ( (XGN) ) has provided an announcement.
On January 11, 2026, Exagen Inc. reported select preliminary unaudited results for the fourth quarter and full year ended December 31, 2025, indicating record annual revenue of $66 million to $67 million, up 19% to 20% year over year, with fourth-quarter revenue projected at $16 million to $17 million, a 17% to 24% increase. The company highlighted continued momentum in its AVISE CTD franchise, with 2025 test volumes rising to 136,000 to 137,000, an 11% increase over 2024, and a trailing 12‑month average selling price of $441 to $445, at least $30 higher than the prior year, despite pricing headwinds in the second half. Year-end cash and cash equivalents improved to $32 million, about $10 million higher than at the end of 2024, underscoring stronger liquidity as Exagen ramps investment in scientific and commercial capabilities and rolls out enhancements to its AVISE platform, moves that reinforce its competitive positioning in autoimmune diagnostics while management continues to target a path to profitability.
The most recent analyst rating on (XGN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.
Spark’s Take on XGN Stock
According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.
Exagen’s stock score is primarily impacted by financial performance challenges and bearish technical indicators. While there is revenue growth and new product potential, profitability issues and technical weakness weigh heavily on the score.
To see Spark’s full report on XGN stock, click here.
More about Exagen
Exagen Inc. is a San Diego County–based provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. Its flagship AVISE CTD test supports earlier and more accurate diagnosis of complex rheumatic diseases such as lupus, rheumatoid arthritis and Sjögren’s syndrome, and the company offers a broader AVISE-branded portfolio for diagnosis, prognosis and monitoring, targeting rheumatologists and other specialists managing autoimmune disease.
Average Trading Volume: 343,983
Technical Sentiment Signal: Sell
Current Market Cap: $139.8M
See more insights into XGN stock on TipRanks’ Stock Analysis page.